Vaccination and Autoimmunity

Carlo Perricone*, Fabrizio Conti, Nancy Agmon-Levin, Guido Valesini, Yehuda Shoenfeld

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Chronic infection with the hepatitis C virus (HCV) is among the most common aetiologic factors influencing vasculitis in humans. Long-term infection is associated with small-vessel vasculitis (HCV-associated cryoglobulinemic vasculitis [CV]) in less than 5% of cases, and it is associated more rarely with medium-size vasculitis (polyarteritis nodosa-like). In recent years, significant advances have been made in our understanding of the pathogenesis of HCV-associated CV and its long-term prognosis. Furthermore, new immunosuppressive agents such as rituximab (a B cell-depleting agent) have been shown to be efficacious with limited toxicity, providing a promising alternative to current immunosuppressives for the treatment of HCV-associated CV. This chapter presents the pathogenesis, clinical features and recent therapeutic options for HCV-associated CV and medium-size vasculitis.

Original languageEnglish
Title of host publicationInfection and Autoimmunity
PublisherElsevier Inc.
Number of pages26
ISBN (Print)9780444632692
StatePublished - 1 Jan 2015


  • Cryoglobulins
  • Hepatitis C virus
  • Rituximab
  • Vasculitis


Dive into the research topics of 'Vaccination and Autoimmunity'. Together they form a unique fingerprint.

Cite this